• Login | Register | Sign up for e-Newsletters

Conference Details - Overview

10th International Lung Cancer Congress

The Fairmont Orchid
Kohala Coast, HI
Jun 17-20, 2009

Conference Overview

Summary and Purpose

Oncology CME-Certified Congress

The purpose of the 10th International Lung Cancer Congress is to update participants on advances in lung cancer, including biology, pathology, staging, individualized therapy, novel agents, and supportive care. The congress will discuss current trends in surgical, radiotherapeutic, and chemotherapeutic approaches to lung cancer and will provide a perspective on clinical data presented at major international oncology meetings. An ongoing focus will be the individualization of therapy based on clinical, histologic, and molecular characteristics. Areas of controversy in lung cancer therapy, including treatment of early-stage and locally advanced disease, testing for molecular markers, and the optimal combination of targeted and cytotoxic agents will be the subject of panel discussions and debates. The congress will also feature presentations on optimizing the application of established targeted agents as well as presentations introducing emerging targeted agents, including mechanisms of action and clinical/preclinical results. A regular feature of the International Lung Cancer Congress is an update of research efforts from major Cooperative Groups in the United States, Europe, and Asia. The format of the meeting will include didactic lectures from internationally renowned leaders, debates and discussions on controversial topics, extensive panel discussions with case scenarios, multidisciplinary tumor boards, and question-and-answer sessions as well as afternoon translational workshops focusing on strategies currently in development for the treatment of lung cancer.

Follow us on Twitter at www.twitter.com/lungcacongress or text “follow lungcacongress” to 40404.

Target Audience

Learning Objectives

At the conclusion of this congress, you should be able to:

• Summarize clinical data on the efficacy of adjuvant/neoadjuvant chemotherapy for patients with early-stage NSCLC
• Compare the predictive power of tumor stage and molecular profiling in early-stage NSCLC
• Review current issues in the surgical treatment of NSCLC
• Evaluate clinical data on radiation therapy in the treatment of early-stage and locally advanced NSCLC
• Describe combined modality approaches for patients with locally advanced lung cancer
• Assess the feasibility of sublobar resections in early-stage NSCLC
• Summarize the impact of revised staging criteria on lung cancer diagnosis
• Discuss the optimal application of antiangiogenic agents in lung cancer
• Assess approaches to managing toxicities from antiangiogenic agents
• Discuss updates on the use of EGFR TKIs, including the impact of molecular and clinical characteristics and overcoming resistance
• Evaluate clinical data on anti-EGFR antibodies in NSCLC treatment regimens
• Assess clinical data on multikinase inhibitors and epigenetic approaches
• Evaluate approaches to optimize lung cancer therapy based on clinical and molecular characteristics
• Discuss pathologic approaches to categorize lung cancers histologically and molecularly
• Evaluate clinical data on agents used to ameliorate bone health in patients with lung cancer
• Discuss novel cytotoxic and other targeted agents in development for patients with lung cancer
• Evaluate approaches to improve outcomes with frontline and salvage therapy regimens in metastatic NSCLC
• Summarize current research activity in lung cancer from national and regional Cooperative Groups